Actively Recruiting

Phase Not Applicable
Age: 40Years - 69Years
All Genders
NCT07039123

Polygenic Risk Score for Optimizing Primary Prevention in Intermediate-Risk Populations

Led by University of Bern · Updated on 2025-07-25

204

Participants Needed

2

Research Sites

116 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to determine whether incorporating a polygenic risk score (PRS) can optimize primary cardiovascular disease prevention in individuals with intermediate cardiovascular risk. The main questions it aims to answer are: * Can a polygenic risk score improve risk stratification in intermediate-risk individuals? * Does disclosing polygenic risk information to patients and physicians lead to better preventive interventions (e.g., statin use, lifestyle changes)? Researchers will compare outcomes in participants with PRS disclosure versus standard risk assessment to see if PRS-guided prevention leads to improved cardiovascular risk management. Participants will: * Undergo baseline cardiovascular risk assessment * Provide a blood sample for PRS calculation * Complete follow-up visits for lifestyle counseling, medication review, and risk reassessment

CONDITIONS

Official Title

Polygenic Risk Score for Optimizing Primary Prevention in Intermediate-Risk Populations

Who Can Participate

Age: 40Years - 69Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 40 and 69 years
  • Intermediate cardiovascular risk based on SCORE2 or SCORE2-Diabetes
  • Able to understand German or French or have an interpreter
  • Provided written informed consent
Not Eligible

You will not qualify if you...

  • Currently treated with lipid-lowering therapy such as statins, ezetimib, bempedoic acid, or PCSK-9 inhibitors
  • History of cardiovascular disease including coronary artery disease, peripheral artery disease, or ischemic stroke
  • Chronic kidney disease with eGFR below 30 ml/min or below 60 ml/min with albuminuria in diabetic patients with organ damage
  • Participating in another cardiovascular risk or lifestyle intervention clinical trial
  • Life expectancy less than one year

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

University of Bern, Institute of Primary Health Care (BIHAM)

Bern, Switzerland, 3012

Actively Recruiting

2

University of Lausanne, Centre Hospitalier Universitaire Vaudois (CHUV)

Lausanne, Switzerland

Not Yet Recruiting

Loading map...

Research Team

E

Elisavet Moutzouri, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here